tbuckley/cabot-search huggingface dataset:
Association of psychological variables and outcome in tendinopathy: a systematic review
Authors: Adrian Mallows, James Debenham, Tom Walker, Chris Littlewood
Journal: British Journal of Sports Medicine (2016)

Fear, anxiety, depression, distress and catastrophisation are all factors known to affect pain and disability levels. To date, the association of such psychological factors has yet to be established in tendinopathy. Therefore, the purpose of this paper was to determine if psychological variables are associated with tendinopathy and whether any such variables may be associated with pain and disability outcomes in conservative management of tendinopathy.A systematic review was undertaken and included studies were appraised for risk of bias using the Newcastle-Ottawa Scale. Owing to heterogeneity of studies, a qualitative synthesis was undertaken.An electronic search of MEDLINE, CiNAHL, SPORTDiscus, PsycINFO, EMBASE and PsycARTICLES was undertaken from their inception to April 2016.Any study design that incorporated psychological measures and clinical outcomes using participants with tendinopathy.Ten articles describing nine studies and 1108 participants were included. Conflicting evidence exists regarding the association of anxiety, depression and lateral epicondylalgia (LE). Strong evidence suggests LE is not associated with kinesiophobia. Moderate evidence links catastrophisation and distress with LE. Moderate evidence suggests distress is not associated with rotator cuff tendinopathy, but kinesiophobia and catastrophisation are. Limited evidence suggests patellar tendinopathy is not associated with anxiety or depression and kinesiophobia may be linked with suboptimal outcomes in Achilles tendinopathy.Tendinopathy requires an individualised approach to management. Clinicians should consider using validated screening tools for the presence of psychological variables as a part of their holistic management.
OP0076 Autoantibodies against CD74 – A New Diagnostic Marker for Spondyloarthritis (SPA)
Authors: E. Schweikhard, T. Matthias, S. Reuter, J. Georgi, N. Baerlecken, T. Witte, M. Köhler
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Spondyloarthritis (SpA) is a common debilitating inflammatory disorder. Pathogenesis of axial SpA (axSpA) including ankylosing spondylitis (AS) is still largely unclear. <h3>Objectives</h3> Diagnosis is difficult, since abnormalities in conventional X-rays develop with a latency of several years and only HLA-B27 is used as laboratory marker. The presence of radiographic sacroiliitis is essential for SpA diagnosis. To prevent destructive effects early diagnosis and intervention in SpA patients may be important. To evaluate antibodies to the human leukocyte antigen class II-associated invariant chain peptide (anti-CD74) as a diagnostic marker of SpA. <h3>Methods</h3> Sera of 117 patients with axial SpA and 38 non-SpA patients were analyzed for IgA and IgG antibodies against CD74 by ELISA. HLA-B27 status was available in 112 patients. All donors provided informed consent for the study approved by the local ethics committee (project number 4928). <h3>Results</h3> Anti-CD74 antibodies were detected in 85.1% of SpA patients but only in 5% of non-SpA patients (p≤0.0001). Detection of both IgG and IgA anti-CD74 antibodies for diagnosing SpA revealed a sensitivity of 77% and a specificity of 90%. Remarkably, IgA autoantibodies against CD74 alone had a sensitivity of 67% and a specificity of 95%. IgA anti-CD74 antibodies were even more frequent in SpA patients with short disease duration and significantly correlate with more advanced radiological sacroiliitis and reduced spinal mobility. <h3>Conclusions</h3> Anti-CD74 IgA antibodies were strongly associated with SpA. Antibodies against CD74 could provide an important additional tool for diagnosis of SpA. <h3>Disclosure of Interest</h3> None declared
Imetelstat, A Potent Telomerase Inhibitor, Inhibits the Spontaneous Growth of CFU-Meg In Vitro From Essential Thrombocythemia Patients but Not From Healthy Individuals,
Authors: Claudio Brunold, Thomas R Braschler, Ning Go, Joi Ninomoto, Hooman Kashani, Monic J. Stuart, Elisabeth Oppliger Leibundgut, Gabriela M. Baerlocher
Journal: Blood (2011)
Differential Gene Expression in Leukemic Cells from Bone Marrow (BM) and Peripheral Blood (PB) of Pediatric Patients with Acute Lymphoblastic Leukemia (ALL).
Authors: Peter Rhein, Stefanie Scheid, Christian Hagemeier, Karl Seeger, Renate Kirschner, Martin Schrappe, Rainer Spang, Wolf-Dieter Ludwig, Leonid Karawajew
Journal: Blood (2004)
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Large Single-Center Experience: Analysis of Clinical and Molecular Characteristics and Patient Outcomes
Authors: Naveen Pemmaraju, Hagop M. Kantarjian, Jorge E. Cortes, Madeleine Duvic, Joseph D Khoury, Keyur Patel, Naval Daver, Susan O'Brien, Sherry Pierce, Guillermo Garcia-Manero, Elias Jabbour, Nitin Jain, Stefan Faderl, Deborah Thomas, Arthur E. Frankel, Muzaffar H. Qazilbash, Marina Konopleva
Journal: Blood (2015)
AB0187 Influence of Educational Level on The Outcomes of Rheumatoid Arthritis
Authors: F. Essafi, A. Fazaa, S. Kchaou, K. Ben Abdelghani, S. Kassab, S. Chkili, A. Laatar, L. Zakraoui
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Formal educational background has been associated with a worse health outcome and greater disease activity among patients with Rheumatoid Arthritis (RA). <h3>Objectives</h3> The aim of this study was to evaluate the influence of educational level on the outcomes of RA, in terms of disease activity and functional impairment. <h3>Methods</h3> This is a cross-sectional study, including patients with RA (1987 ACR criteria). Disease activity was evaluated by erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and Disease Activity Score (DAS28) ESR. Functional disability was assessed by Health Assessment Questionnaire (HAQ). Patients were classified according to their educational level into 4 categories: illiterate, primary, secondary or university levels. Statistical analysis was done using one-way analysis of variance (ANOVA) and linear regression models. The significance level was set at p&lt;0.05. <h3>Results</h3> A total of 67 patients with RA were evaluated, 5 men and 62 women. The mean age was 53 years [28–75] and the mean disease duration was 9.19 years [1–30]. Eighty eight percent of patients were treated with synthetic DMARDs (Disease modifying antirheumatic drugs) and 20% were treated with biologic DMARDs. With regard to the educational level, 34.3% were illiterate, 20.89% had primary level, 34.3% secondary level and 10.44% had university level There were no statistically significant differences for ESR, CRP, DAS28 and HAQ when comparing the four educational levels (p=0.176, p=0.252, p=0.528, p=0.410, respectively). However, in the multivariate analysis, after adjusting for age and biologic DMARDs, DAS28 and HAQ were significantly associated to the educational level (p=0.024, p=0.014, respectively). <h3>Conclusions</h3> This study shows that educational levels may have an influence on the disease activity and functional impairment in patients with RA. <h3>Disclosure of Interest</h3> None declared
PTU-015 Colonoscopic Perforation: What are the Indicators for Conservative Management?: Abstract PTU-015 Table 1
Authors: E Derbyshire, AP Hungin, MD Rutter
Journal: Gut (2016)

<h3>Introduction</h3> Perforation is one of the most serious adverse events associated with colonoscopy and may be managed conservatively or surgically. We have previously reported outcomes following colonoscopic perforations in the English National Health Service Bowel Cancer Screening Programme, showing that those perforations managed conservatively with bowel rest, intravenous fluids and antibiotics did not develop post perforation morbidity.<sup>1</sup> We therefore aimed to examine which factors could be used as indicators for conservative management. <h3>Methods</h3> We re-evaluated our national database of 115 colonoscopic perforations admitted to hospital, including 62 patients who had surgery and 51 who didn’t (two patients in whom it was unclear if surgery had occurred were excluded from the analysis). Explanatory variables examined were admission immediately following colonoscopy, the presence of abdominal pain at initial review, initial temperature, pulse rate and respiratory rate (RR). Statistical Analysis was performed using Statistical Package for the Social Sciences version 20. Fisher’s exact test and pearson chi-square were used to test association between explanatory and outcome variables with a p value &lt;0.05 considered to be significant. <h3>Results</h3> 15.0% of the patients had none of: abdominal pain at initial review, a pulse rate &gt; 100 beats per minute or a RR &gt; 20 breaths per minute. 23.5% of these patients had surgery. <h3>Conclusion</h3> The presence of abdominal pain, a pulse rate &gt; 100 beats per minute and RR &gt; 20 breaths per minute were significantly associated with the patient having surgery. Small numbers of patients with no abdominal pain, a pulse rate ≤ 100 beats per minute and a RR ≤ 20 breaths per minute underwent surgery. It is unclear from this retrospective data whether this surgery was actually necessary. It is possible that the absence of abdominal pain, a pulse rate ≤ 100 beats per minute and a RR ≤ 20 breaths per minute may be useful objective measures to determine whether surgery is required. Further prospective work using these indicators to guide conservative management is required. <h3>Reference</h3> 1 Derbyshire, <i>et al</i>. <i>UEG Journal</i> October 2015;<b>3</b>:1–145. <h3>Disclosure of Interest</h3> None Declared
Adhesion Molecule Blockade with the Humanized Anti-LFA-1 Monoclonal Antibody Efalizumab Improves Steroid Refractory Acute and Chronic Graft-Versus-Host Disease of the Skin
Authors: James M. Coghill, Kristine E. Nograles, James G. Krueger, Amy S. Coghill, Jonathan S. Serody, Anastasia Ivanova, Julia Whitley, Donald Gabriel, Terrance Comeau, Thomas Shea
Journal: Blood (2008)
A Novel and Significant Predictor in Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: The Prognostic Nutritional Index (PNI)
Authors: Qingqing Cai, Kailin Chen, Huilan Rao, Wenqi Jiang, Huiqiang Huang, Tongyu Lin, Zhongjun Xia
Journal: Blood (2014)
AML1/Runx1 Negatively Regulates the Number of Quiescent Hematopoietic Stem Cells in Adult Hematopoiesis.
Authors: Motoshi Ichikawa, Takashi Asai, Masahiro Nakagawa, Masahito Kawazu, Susumu Goyama, Masataka Takeshita, Shigeru Chiba, Seishi Ogawa, Mineo Kurokawa
Journal: Blood (2006)
Refined Disease Risk Index (DRI) and Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Predict Survival after Haploidentical Stem Cell Transplantation: A Comparative Study with EBMT Risk Score in 220 Consecutive Patients
Authors: Maria Teresa Lupo-Stanghellini, Elisa Sala, Simona Piemontese, Mara Morelli, Raffaella Greco, Magda Marcatti, Andrea Assanelli, Matteo G Carrabba, Forcina Alessandra, Sara Mastaglio, Sarah Marktel, Francesca Lorentino, Francesca Lunghi, Elena Guggiari, Fabio Giglio, Malato Simona, Francesca Pavesi, Carlo Messina, Luca Vago, Consuelo Corti, Massimo Bernardi, Jacopo Peccatori, Fabio Ciceri
Journal: Blood (2015)
Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response
Authors: Bryan J. Schneider, Manish A. Shah, Kelsey Klute, Allyson Ocean, Elizabeta Popa, Nasser Altorki, Michael Lieberman, Andrew Schreiner, Rhonda Yantiss, Paul J. Christos, Romae Palmer, Daoqi You, Agnes Viale, Pouneh Kermani, Joseph M. Scandura
Journal: Clinical Cancer Research (2016)

Abstract Purpose: Epigenetic silencing of tumor suppressor genes (TSG) is an acquired abnormality observed in cancer and is prototypically linked to DNA methylation. We postulated that pretreatment (priming) with 5-azacitidine would increase the efficacy of chemotherapy by reactivating TSGs. This study was conducted to identify a tolerable dose of 5-azacitidine prior to EOX (epirubicin, oxaliplatin, capecitabine) neoadjuvant chemotherapy in patients with locally advanced esophageal/gastric adenocarcinoma (EGC). Experimental Design: Eligible patients had untreated, locally advanced, resectable EGC, ECOG 0–2, and adequate organ function. 5-Azacitidine (V, 75 mg/m2) was given subcutaneously for 3 (dose level, DL 1) or 5 (DL 2) days prior to each 21-day cycle of EOX (E, 50 mg/m2; O, 130 mg/m2; X, 625 mg/m2 twice daily for 21 days). Standard 3+3 methodology guided V dose escalation. DNA methylation at control and biomarker regions was measured by digital droplet, bisulfite qPCR in tumor samples collected at baseline and at resection. Results: All subjects underwent complete resection of residual tumor (R0). Three of the 12 patients (25%) achieved a surgical complete response and 5 had partial responses. The overall response rate was 67%. The most common toxicities were gastrointestinal and hematologic. Hypomethylation of biomarker genes was observed at all dose levels and trended with therapeutic response. Conclusions: Neoadjuvant VEOX was well-tolerated with significant clinical and epigenetic responses, with preliminary evidence that priming with V prior to chemotherapy may augment chemotherapy efficacy. The recommended phase II trial schedule is 5-azacitidine 75 mg/m2 for 5 days followed by EOX chemotherapy every 21 days. Clin Cancer Res; 23(11); 2673–80. ©2016 AACR.
Bortezomid-Induced Sweet Syndrome.
Authors: Aline A. Schmidt-Tanguy, Martine M. Avenel-Audran, Séverine S. Lissandre, Mammoun M. Dib, Anne A. Croue, Marie-Pierre M.P. Moles, Norbert N. Ifrah, Mathilde M. Hunault-Berger
Journal: Blood (2006)
Over-Expression of Novel IRF8 Splice Variants Is Associated with a Significant Decrease In Relapse-Free Survival In Adult AML Patients.
Authors: Era L. Pogosova-Agadjanyan, Kenneth J. Kopecky, Hana Lee, Jeanne E. Anderson, John E. Godwin, Alan F. List, Soheil Meshinchi, Vivian Oehler, Stephen H. Petersdorf, Cheryl L. Willman, Frederick R. Appelbaum, Jerald P. Radich, Derek L. Stirewalt
Journal: Blood (2010)
Single High-Dose Chemoradiotherapy Versus Tandem High Dose Melphalan Followed by Auto-SCT for Advanced Multiple Myeloma. Preliminary Analysissis.
Authors: Hermann Einsele, Peter Liebisch, Ralf Bargou, Christoph Meisner, Bernd Metzner, Hannes Wandt, Hans-Heinrich Wolf, Orhan Sezer, Jochen Casper, Michael Pfreundschuh, Georg Maschmeyer, Christian Straka, Lothar Truemper, Nikolaus Kroeger, Peter Mueller, Bernd Hertenstein, Nikolaus Frickhofen, Paolo Coser, Michael Bamberg, Holger Hebart, Lothar Kanz
Journal: Blood (2004)
Concurrent Rituximab with Dose-Dense MegaCEOP Chemotherapy and High Dose Mitoxantrone, Ara-C and Dexamethasone (MAD) Followed by BEAM and Autologous Stem Cell Transplantation (ASCT) Is Feasible and Effective in High Risk Diffuse Large B-Cell Lymphoma (B-DLCL): A Multicenter Pilot Study.
Authors: Umberto Vitolo, Anna Marina Liberati, Maria Giuseppina Cabras, Giuseppe Rossi, Alessandro Levis, Enzo Pavone, Emanuele Angelucci, Carola Boccomini, Lisa Bonello, Barbara Botto, Annalisa Chiappella, Francesco Di Vito, Isabella Palumbo, Enrico Pogliani, Delia Rota-Scalabrini, Flavia Salvi, Anna Tonso, Alessandra Tucci, Eugenio Gallo
Journal: Blood (2004)
Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias
Authors: Andrew Dunford, David M Weinstock, Virginia Savova, Steven E Schumacher, John P Cleary, Akinori Yoda, Timothy J Sullivan, Julian M Hess, Alexander A Gimelbrant, Rameen Beroukhim, Michael S Lawrence, Gad Getz, Andrew A Lane
Journal: Nature Genetics (2016)
Taming chronic cough
Authors: Jaclyn A Smith, Jemma Haines, Janelle Yorke
Journal: Thorax (2016)

Non-pharmacological therapy to treat chronic cough was first described in the 1980s, in patients thought to be suffering from ‘habit’ or ‘psychogenic’ cough.1 ,2 Improvements were reported with the application of speech and language therapy techniques originally developed for a variety of voice disorders, accompanied by individualised psychotherapeutic approaches. Twenty years later, Ann Vertigan published the first randomised controlled trial evidence that speech and language therapy techniques improved symptoms scores for cough, breathing, voice and upper airway symptoms in patients with refractory chronic cough attending a single hospital service.3 This study delivered an intervention based on the original reports, comprising four elements: education about the nature of chronic cough, strategies to control the cough, psychoeducational counselling and vocal hygiene education to reduce laryngeal irritation. Following this single study, many clinical cough services have implemented speech and language therapy,4 largely motivated by the limited treatment options for chronic cough, which can be severe and disabling. However, an important outstanding question has been whether such inventions can be successfully applied in other settings and by therapists from other disciplines.

In Thorax , Chamberlain et al 5 replicate Vertigan's findings in the first multicentre randomised controlled trial of PSALTI (Physiotherapy, Speech and Language Therapy Intervention), demonstrating a significant improvement in cough-specific quality of life and an estimated 40% reduction in cough frequency in refractory chronic cough. An intervention similar to Vertigan's was delivered by either speech and language therapists or physiotherapists, and improvements in cough were captured using …
Persistence of antibodies acquired by natural hepatitis E virus infection and effects of vaccination
Authors: Y.-Y. Su, S.-J. Huang, M. Guo, J. Zhao, H. Yu, W.-G. He, H.-M. Jiang, Y.-J. Wang, X.-F. Zhang, J.-P. Cai, C.-L. Yang, Z.-Z. Wang, F.-C. Zhu, T. Wu, J. Zhang, N.-S. Xia
Journal: Clinical Microbiology and Infection (2016)
5-Azacytidine and Decitabine Induce Demethylation and Re-Expression of FAS (CD95) and Promote Apoptosis in Neoplastic Cells in Acute Myeloid Leukemia (AML),
Authors: Heidrun Karlic, Rene Reitermaier, Viviane Ghanim, Harald Herrmann, Roman Thaler, Silvia Spitzer, Franz Varga, Irina Sadovnik, Katharina Blatt, Felix Keil, Peter Valent, Michael Pfeilstöcker
Journal: Blood (2011)
THU0557 Reliability and Validity of Turkish Version of The fibromyalgia Rapid Screening Tool (First)
Authors: R. Çeliker, L. Altan, A. Rezvani, I. Aktaş, N. Taştekin, E. Dursun, N. Dursun, S. Sarıkaya, S. Özdolap, K. Akgün, C. Zateri, M. Birtane
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Fibromyalgia is a challenging chronic pain condition accompanied by several comorbidites. Since patients are encountered in various health care settings, there is a need for short, easy to use, psychometrically validated screening tool <h3>Objectives</h3> This study aims to evaluate reliability and validity of Turkish version of Fibromyalgia Rapid Screening Tool (FiRST) by correlating this tool with 2013 American College of Rheumatology alternative diagnostic criteria (ACR AltCr) and Hospital Anxiety and Depression Scale (HADS). <h3>Methods</h3> A convenience sample of 269 subjects recruited from outpatient Physical Medicine and Rehabilitation clinics were included in the study. Patients were asked to complete the questionnaire including FiRST (twice), 2013 AltCr and HADS. The reliability of the FiRST scale was examined by test-retest method. For criterion validity of FiRST scale, we used ACR 2013AltCr for comparison. The concordance between ACRAltCr and FiRST and the relationships between variables were evaluated. The sensitivity, specificity, positive and negative likelihood ratios of FiRST was calculated according to ACR 2013 AltCr criteria. Logistic regression analysis was carried out to find the confounding effect of HADS on FiRST to discriminate the patients with FMS <h3>Results</h3> The test-retest reliability coefficient of FiRST scale was r=0.875. FiRST was similar to ACR 2013 AltCr in defining patients with FMS. FiRST score was correlated with subscores of ACR 2013AltCr. Each point increase in FiRST global score increased odds of suffering FM approximately 10 times compared to HADS <h3>Conclusions</h3> Turkish version of FiRST is a reliable instrument for identifying patients with FMS <h3>Disclosure of Interest</h3> None declared
AB0905 The Expanding Spectrum of Inflammatory Diseases Associated with Mefv Gene Mutations: Table 1.
Authors: F. Cosan, Z.A. Cetinkaya
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Familial Mediterranean fever is an autoinflammatory disease with recurrent inflammatory attacks. The genetic cause of FMF is the mutations in the MEFV gene coding pyrin, which has role in the activation of inflammasome, acitvation of caspase 1 and production of IL-1B. The impaired function of MEFV gen results increased systemic inflammation. It is shown that MEFV mutations can have effect on some other inflammatory diseases as contributing the disease development or increased inflammation or severe disease duration. <h3>Objectives</h3> It is reported several articles about the association between MEFV mutations and different inflammatory diseases. We aimed in this study to analyse the MEFV gene associated diseases with a systematic review. <h3>Methods</h3> We searched databases for articles about MEFV gene mutations (MEFVm). We excluded the articles including FMF patients. 92 research articles were included our study which analysed the MEFV gene mutations in inflammatory diseases except FMF. <h3>Results</h3> Inflammatory bowel disease (IBD), Behçet9s disease (BD), HSP, ankylosing spondylitis (AS), PFAPA, JIA, ischemic heart disease (IHD) were disorders which are associated increased MEFV gene mutation rate and it is shown in these diseases that MEFVm have disease modifying effect. Rheumatoid arthritis and SLE studies have shown no significant difference in MEFVm rates, but MEFVm are related with some clinical findings. The MEFVm carrier frequency was increased in seronegative arthritis, adult onset Still disease (AOSD), fibromiyalgia, dismenorrhea, chronic renal failure, hematolymphoid neoplasms (ALL, MM, MDS, PV). The study design of these disorders doesn9t include to investigate the relationship of MEFVm with the disease activity. It was found any association with MEFVm in gouty arthritis, rheumatic heart disease, uveitis,idiopatic pericarditis, tip I Diabetes Mellitus and osteoarthritis. The detailed data is shown in Table-1. <h3>Conclusions</h3> MEFV mutations may have effect in the develeopment of inflammatory diseases and may modify the clinical findings. This modifying effect may be important especially in countries with high MEFVm mutation carrier rate. <h3>Disclosure of Interest</h3> None declared